TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04270760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olpasiran
Description: Dose 1 Dose 2 Dose 3 Dose 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olpasiran
Description: Dose 1 Dose 2 Dose 3 Dose 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olpasiran
Description: Dose 1 Dose 2 Dose 3 Dose 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olpasiran
Description: Dose 1 Dose 2 Dose 3 Dose 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose 5
Study: NCT01002092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: In each cycle, Week 1-2 day 1-14 endostar 7.5 mg/m2/day; Week 5-6 day 1-14 endostar 7.5 mg/m2/day
Study: NCT05855512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Educational Intervention
Description: Nursing Educational Intervention
Study: NCT04415073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNDX-6352
Description: SNDX-6352

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT01076465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disease management program
Description: 1. Educational intervention on management of heart failure and comorbidity to improve patient's knowledge of his/her disease and self-care 2) Monitoring of clinical status 3) Monitoring and improvement of therapeutic adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care
Study: NCT03329456

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: Minimum effective volume
Study: NCT04520529

Intervention type: OTHER
Group type: OTHER
Intervention: Biologic Samples
Description: * An additional punch from lesion skin as part of a skin biopsy performed as part of routine care.~* an additional blood sample will be collected for research during a blood test performed as part of the patient's routine care.~* In patients with clinical superficial lymphadenopathy or detected by imaging, and undergoing a superficial lymph node biopsy as part of the care, a core biopsy will be dedicated to research.
Study: NCT04732390

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: erector spinae block with bupivacaine
Description: Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5
Study: NCT01992809

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3
Description: Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA \[α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%\], in 3 capsules/ day
Study: NCT03242330

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subperiosteal implant
Description: Subperiosteal implants are placed and fitted 'onto' the jaw bone just right below the mucoperiosteum; where the post of the metal frame is in a protruding position through the mucosa holding the prosthesis that will be later fitted.
Study: NCT04732390

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block with bupivacaine and magnesium sulphate
Description: Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5.
Study: NCT02183740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted educational program
Study: NCT05606029

Intervention type: PROCEDURE
Intervention: Cholecystectomy, extended cholecystectomy
Description: Cholecystectomy and histopathological evaluation
Study: NCT03242330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subperiosteal implant
Description: Subperiosteal implants are placed and fitted 'onto' the jaw bone just right below the mucoperiosteum; where the post of the metal frame is in a protruding position through the mucosa holding the prosthesis that will be later fitted.
Study: NCT01099202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procrit (epoetin alfa)
Description: Starting dose 40,000 Units subcutaneously once a week during your regularly scheduled chemotherapy for up to 6 courses of chemotherapy (around 5 months).
Study: NCT00740610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450
Description: GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450
Description: GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
Study: NCT03546855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg/d po,28 days as one cycle
Study: NCT00664248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-110
Description: Topical application for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Topical application for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl peroxide
Description: Topical application for 12 weeks
Study: NCT00740610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450
Description: GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450
Description: GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GS-9450 Placebo
Description: Placebo to match GS-9450 administered orally once daily
Study: NCT03820440

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: End-expiratory occlusion test (EEOT)
Description: The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung recruitment manovre (LRM)
Description: The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds
Study: NCT00664248

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical application for 12 weeks
Study: NCT00200850

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: House Dust Mite SLIT
Description: low dose SLIT 143 Allergen Units(AU)/ml daily

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High dose SLIT
Description: House Dust Mite SLIT- 10,000 Allergen units(AU)/ml daily

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SLIT
Description: Placebo SLIT daily
Study: NCT01864408

Intervention type: OTHER
Group type: OTHER
Intervention: Usual practice counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard usual practice clinical counseling with the pelvic organ prolapse web-based tool (iPad).
Description: After a new patient history and physical exam, with POP-Q exam, the subjects specific exam findings are entered into the Interactive Pelvic Organ Prolapse Quantification (POP-Q) Program. The program then constructs a cartoon of the subjects physical exam findings. This image is then used in counseling in addition to standard usual practice counseling.
Study: NCT00700180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin-based chemotherapy
Description: As prescribed
Study: NCT04221477

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching obinutuzumab will be administered by IV infusion at baseline and Weeks 0, 2, 24, 26, 50 and 52 and subsequently from Week 80 and every 6 months thereafter based on response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 80 mg IV will be administered as predmedication prior to infusions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 80 mg IV will be administered as predmedication prior to infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
Study: NCT00799851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Variceal band ligation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyanoacrylate injection
Description: cyanoacrylate injection
Study: NCT04235413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-Time Incentives Group
Description: The use of a novel computer program with a mobile phone interface to provide real-time financial incentives at the point of purchase for discounts on fruit and vegetables in low-income families. This intervention will be applied to subjects randomized to the intervention arm. They will receive 50% off eligible fruits and vegetable products at the point of purchase, up to $10 a week for 6 months. Maximum amount they can receive is $260 in discounts over the 6 month period.
Study: NCT02226445

Intervention type: OTHER
Intervention: Combined ADHD medication and psychosocial counseling
Description: The patients are offered as well ADHD medication as non-standardized psychosocial treatment, the latter including psychoeducation (i.e. information about ADHD aetiology and symptoms plus management of symptoms) and counselling regarding emotional-, family- and social rehabilitation-related problems.~ADHD medication:~First choice of medication is methylphenidate immediate release, initially 5 mg 2-3 times a day increasing with 10-20 mg per week up to stabilization of symptoms.~When stabilized a shift to extended release methylphenidate. Alternatively dexamphetamine, initially 2.5 mg 2-3 times a day increasing with 5-10 mg per week up to stabilization of symptoms.~If there is no adequate effect of central stimulants then a shift to atomoxetine, initially 18 mg a day, increasing during a period of 6-10 weeks up to max. 100 mg a day.~If the patients have a substance use, an anxiety problem or other contraindications then first choice of medication is atomoxetine.
Study: NCT01610999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor will be dosed according to actual body weight. Each dose will be capped at 24 mg (single vial). Plerixafor will be administered subcutaneously according to the assigned cohort starting two hours before the scheduled start of high dose chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor will be dosed according to actual body weight. Each dose will be capped at 24 mg (single vial). Plerixafor will be administered subcutaneously according to the assigned cohort starting two hours before the scheduled start of high dose chemotherapy.
Study: NCT03683732

Intervention type: BEHAVIORAL
Intervention: Individual semi-structured interviews
Description: Individual semi-structured interviews were conducted using purposeful sampling of 15- to 18-year-olds, until data saturation, and were transcribed and analysed
Study: NCT00179491

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intercessory Prayer
Description: 14 days of intercessory prayer from 3 sites

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intercessory Prayer
Description: 14 days of intercessory prayer from 3 sites
Study: NCT04221477

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg will be administered as premedication prior to infusions.
Study: NCT01943253

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ESD
Description: Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany; Olympus Japan) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
Study: NCT00700180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin-based chemotherapy
Description: As prescribed
Study: NCT01943253

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybridknife ESD
Description: Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)
Study: NCT04221477

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg will be administered as premedication prior to infusions.
Study: NCT03227146

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EHSG-KF
Description: Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EHSG-KF
Description: Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: STSG
Description: Transplantation of autologous split-thickness skin graft to the control area

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: STSG
Description: Transplantation of autologous split-thickness skin graft to the control area
Study: NCT02668471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: ultrasound at radial site and measure the size and depth of radial artery and perform radial artery cannulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional method
Description: Radial artery catheters will be placed by the palpation technique only.
Study: NCT01989468

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 150 mg provided in a 1 mL autoinjector (1 autoinjector for 150 mg dose, 2 autoinjectors for 300 mg dose)
Study: NCT01548001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: 25 mg/tablet, taken orally, 2 tablets/day (bid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: 25 mg/tablet, taken orally, 2 tablets/day (bid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 2.5 mg/tablet, taken orally once a week, 4 tablets/week (week 1-week 4) , 6 tablets/week (week 5- week 52)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 2.5 mg/tablet, taken orally once a week, 4 tablets/week (week 1-week 4) , 6 tablets/week (week 5- week 52)
Study: NCT01693315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMA0076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMA0076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMA0076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMA0076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01629797

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational script on Acne
Description: An educational script on Acne will be presented by investigator
Study: NCT02470455

Intervention type: DRUG
Intervention: Atorvastatin
Description: Some patients were receiving 20 mg of Atorvastatin wheras others were on a higher dose of 40-80mg daily. Patients were taking statins for either dyslipidemia, or primary or secondary prevention of cardiovascular disease.

Intervention type: DRUG
Intervention: Atorvastatin
Description: Some patients were receiving 20 mg of Atorvastatin wheras others were on a higher dose of 40-80mg daily. Patients were taking statins for either dyslipidemia, or primary or secondary prevention of cardiovascular disease.

Intervention type: DRUG
Intervention: Atorvastatin
Description: Some patients were receiving 20 mg of Atorvastatin wheras others were on a higher dose of 40-80mg daily. Patients were taking statins for either dyslipidemia, or primary or secondary prevention of cardiovascular disease.
Study: NCT02468648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5816
Description: An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.
Study: NCT02521701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFL101
Description: Level 1: 100 µg~* 50 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.~Level 2: 200 µg~* 100 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL.
Study: NCT01183624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Patch
Description: 1 herbal patch applied for approximately 8 hours per day for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Control patch with no herbal ingredients
Study: NCT02634580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Tablet for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Tablet for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Ezetimibe
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Ezetimibe
Description: Tablet for oral administration
Study: NCT01197365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula with GOS, beta-palmitate, acidified milk
Description: Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae

Intervention type: OTHER
Group type: OTHER
Intervention: Standard infant formula without functional ingredients
Description: Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
Study: NCT03118297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate
Description: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
Study: NCT02268435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib plus imatinib
Description: Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
Study: NCT02821858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV 50 mg (1 tablet) in Treatment A, 100 mg (2 tablets of 50 mg) in Treatment B and 300 mg (6 tablets of 50 mg) in Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV 50 mg (1 tablet) in Treatment A, 100 mg (2 tablets of 50 mg) in Treatment B and 300 mg (6 tablets of 50 mg) in Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV 50 mg (1 tablet) in Treatment A, 100 mg (2 tablets of 50 mg) in Treatment B and 300 mg (6 tablets of 50 mg) in Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 400 mg (1 tablet) in Treatment D, 800 mg (2 tablets of 400 mg) in Treatment E and 1200 mg (3 tablets of 400 mg) in Treatment F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 400 mg (1 tablet) in Treatment D, 800 mg (2 tablets of 400 mg) in Treatment E and 1200 mg (3 tablets of 400 mg) in Treatment F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL-335 400 mg (1 tablet) in Treatment D, 800 mg (2 tablets of 400 mg) in Treatment E and 1200 mg (3 tablets of 400 mg) in Treatment F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.